SEC Form 4 · accession 0001209191-18-003005
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Tarriff
Officer — CEO · Director
Period of report
Jan 7, 2018
Accepted (ET)
Jan 9, 2018 · 5:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $59.14 | Jan 7, 2018 | A | 157,000 | A | — | Jan 7, 2028 | Common Stock | 157,000 | 157,000 | D |
| Peformance Stock UnitF3,F2,F4 | — | Jan 7, 2018 | A | 189,000 | A | — | Jan 1, 2021 | Common Stock | 189,000 | 189,000 | D |
Explanation of responses
- F1The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 7, 2019, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
- F2Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.
- F3Represents the maximum number of shares issuable under this award.
- F4The shares issuable in respect of such PSUs shall vest on the three-year anniversary of January 1, 2018 (such three-year anniversary, the "Vesting Date"), based on the extent to which the following stock price hurdles are achieved for 30 consecutive trading days on or prior to the Vesting Date. If the Issuer's stock price reaches or surpasses $85.92, $110.00, $120.00 or $134.25, then 63,000, 126,000, 157,500 or 189,000 PSUs will vest, respectively. The number of shares issuable in respect of such PSUs vested on the Vesting Date will be determined by the highest Issuer stock price hurdle achieved. This vesting is subject to the Reporting Person's continuous service with the Issuer as of the Vesting Date.